2016 IATT Paediatric ARV Optimal Formulary List

Developed by the IATT in response to procurement and supply challenges resulting from fragmented demand for paediatric ARVs, and has been developing guidance around the selection of optimal products since 2011, this brief is intended for use by programme managers and policy makers and provides formulary selection and procurement guidance for the optimal paediatric ARV dosage forms needed to provide all WHO recommended 1st and 2nd line regimens while simplifying supply chain and easing administration. The brief includes both the Optimal Paediatric ARV formulary as well as the Limited Use list of those formulations that may be needed in special circumstances. As the Optimal Formulary and Limited Use lists are updated on a regular basis, explanation is provided for updates made since 2013.